Pfizer, AbbVie resolve IP matters for adalimumab biosimilar
Pfizer adalimumab biosimilar update : Pfizer and AbbVie have signed licensing agreements to resolve all global intellectual property (IP) matters
Continue readingCoverage of Global Pharma Industry News
Pfizer adalimumab biosimilar update : Pfizer and AbbVie have signed licensing agreements to resolve all global intellectual property (IP) matters
Continue readingMylan has launched Hulio, a biosimilar to AbbVie’s Humira (adalimumab), in major markets in Europe, a month after its approval
Continue readingGerman pharma company Boehringer Ingelheim said that Cyltezo, a biosimilar to AbbVie psoriasis drug Humira, achieved clinical equivalence to the
Continue readingHyrimoz EC approval : Novartis’ Sandoz has bagged approval for Hyrimoz (adalimumab), a biosimilar of AbbVie’s Humira (adalimumab), in Europe
Continue reading